Literature DB >> 19107331

Cord blood transplantation using minimum conditioning regimens for patients with hematologic malignancies complicated by severe infections.

Takeshi Yamashita1, Chiharu Sugimori1, Ken Ishiyama1, Hirohito Yamazaki1, Hirokazu Okumura1, Yukio Kondo1, Akiyoshi Takami1, Shinji Nakao2.   

Abstract

Patients with severe infections are thought to be ineligible for cord blood stem cell transplantation (CBT) because the conventional 5-6 day-conditioning regimens potentially makes them susceptible to fatal infections by the time neutrophil engraftment occurs. Two patients were treated with minimum conditioning regimens consisting of 30 mg/m(2) fludarabin (Flu) and 2 g/m(2) cyclophosphamide (CY) on day-1 and total body irradiation (TBI) of 2 or 4 Gy on day -1 or 0 followed by single unit CBT. The reasons for adopting such weak regimen were febrile neutropenia due to the rejection of the first cord blood (CB) graft given to a patient with follicular lymphoma resistant to chemotherapy and pulmonary aspergillosis in another patient with AML who relapsed after CBT. The AML patient received 40 mg/m(2) of melphalan on day-2 to reduce the leukemia burden. Both patients achieved 100% donor chimerism by day 19 and day 20 after CBT without an apparent exacerbation of the infections and remained in remission at 23 and 18 months after the CBT. These findings suggest that the 1-2 day regimens excluding antihuman thymocyte globulin may be sufficiently potent to ensure engraftment of CB in immunocompromised patients and safely administered even when patients are complicated by active infections.

Entities:  

Mesh:

Year:  2008        PMID: 19107331     DOI: 10.1007/s12185-008-0234-9

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  20 in total

Review 1.  Second hematopoietic stem cell transplantation for the treatment of graft failure, graft rejection or relapse after allogeneic transplantation.

Authors:  S N Wolff
Journal:  Bone Marrow Transplant       Date:  2002-04       Impact factor: 5.483

2.  Successful engraftment of the second reduced-intensity conditioning cord blood transplantation (CBT) for a patient who developed graft rejection and infectious complications after the first CBT for AML.

Authors:  Y Nakamura; Y Tanaka; T Ando; Y Sato; T Yujiri; Y Tanizawa
Journal:  Bone Marrow Transplant       Date:  2007-06-18       Impact factor: 5.483

3.  Successful second cord blood transplantation using fludarabine and cyclophosphamide as a preparative regimen for graft rejection following reduced-intensity cord blood transplantation.

Authors:  E Mizutani; H Narimatsu; M Murata; A Tomita; H Kiyoi; T Naoe
Journal:  Bone Marrow Transplant       Date:  2007-04-23       Impact factor: 5.483

4.  Successful engraftment by second cord blood transplantation with reduced-intensity conditioning after graft rejection due to hemophagocytic syndrome following initial CBT.

Authors:  H Tanaka; C Ohwada; E Sakaida; Y Takeda; D Abe; K Oda; S Ozawa; N Shimizu; S Masuda; R Cho; M Nishimura; Y Saito; C Nakaseko
Journal:  Bone Marrow Transplant       Date:  2007-09-03       Impact factor: 5.483

5.  Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors.

Authors:  M J Laughlin; J Barker; B Bambach; O N Koc; D A Rizzieri; J E Wagner; S L Gerson; H M Lazarus; M Cairo; C E Stevens; P Rubinstein; J Kurtzberg
Journal:  N Engl J Med       Date:  2001-06-14       Impact factor: 91.245

6.  Successful engraftment of mismatched unrelated cord blood transplantation following reduced intensity preparative regimen using fludarabine and busulfan.

Authors:  Tsunehiko Komatsu; Hiroto Narimatsu; Ai Yoshimi; Naoki Kurita; Manabu Kusakabe; Akiko Hori; Naoko Murashige; Tomoko Matsumura; Kazuhiko Kobayashi; Koichiro Yuji; Yuji Tanaka; Masahiro Kami
Journal:  Ann Hematol       Date:  2006-10-12       Impact factor: 3.673

7.  Protective conditioning for acute graft-versus-host disease.

Authors:  Robert Lowsky; Tsuyoshi Takahashi; Yin Ping Liu; Sussan Dejbakhsh-Jones; F Carl Grumet; Judith A Shizuru; Ginna G Laport; Keith E Stockerl-Goldstein; Laura J Johnston; Richard T Hoppe; Daniel A Bloch; Karl G Blume; Robert S Negrin; Samuel Strober
Journal:  N Engl J Med       Date:  2005-09-29       Impact factor: 91.245

8.  The Japanese cord blood bank network experience with cord blood transplantation from unrelated donors for haematological malignancies: an evaluation of graft-versus-host disease prophylaxis.

Authors:  Hirokazu Nishihira; Koji Kato; Keiichi Isoyama; Tsuneo A Takahashi; Shunro Kai; Shunichi Kato; Minoko Takanashi; Norihiro Sato; Hiroyuki Sato; Kohichi Kitajima; Tomoki Naoe; Hidehiko Saito
Journal:  Br J Haematol       Date:  2003-02       Impact factor: 6.998

9.  Reduced-intensity conditioning followed by unrelated umbilical cord blood transplantation for advanced hematologic malignancies: rapid engraftment in bone marrow.

Authors:  Mahito Misawa; Shunro Kai; Masaya Okada; Toshiyuki Nakajima; Kaori Nomura; Takeshi Wakae; Akinari Toda; Hisayuki Itoi; Hiroyuki Takatsuka; Takeyoshi Itsukuma; Keisuke Nishioka; Yoshihiro Fujimori; Hiroyasu Ogawa; Hiroshi Hara
Journal:  Int J Hematol       Date:  2006-01       Impact factor: 2.490

10.  Outcomes among 562 recipients of placental-blood transplants from unrelated donors.

Authors:  P Rubinstein; C Carrier; A Scaradavou; J Kurtzberg; J Adamson; A R Migliaccio; R L Berkowitz; M Cabbad; N L Dobrila; P E Taylor; R E Rosenfield; C E Stevens
Journal:  N Engl J Med       Date:  1998-11-26       Impact factor: 91.245

View more
  3 in total

1.  Feasibility of salvage cord blood transplantation following fludarabine, melphalan and low-dose TBI for graft rejection after hematopoietic stem cell transplantation.

Authors:  K Ishiyama; J Takeda; T Kondo; N Sugimoto; H Kawabata; T Kitano; A Takaori-Kondo
Journal:  Bone Marrow Transplant       Date:  2016-02-15       Impact factor: 5.483

2.  Graft failure in cord blood transplantation successfully treated with short-term reduced-intensity conditioning regimen and second allogeneic transplantation.

Authors:  Masahiko Sumi; Ikuo Shimizu; Keijiro Sato; Toshimitsu Ueki; Daigo Akahane; Mayumi Ueno; Naoaki Ichikawa; Shinji Nakao; Hikaru Kobayashi
Journal:  Int J Hematol       Date:  2010-11-05       Impact factor: 2.490

3.  Feasibility of salvage cord blood transplantation using a fludarabine, melphalan, and low-dose anti-thymocyte globulin conditioning regimen.

Authors:  Takumi Hoshino; Satoru Takada; Nahoko Hatsumi; Toru Sakura
Journal:  Int J Hematol       Date:  2019-02-08       Impact factor: 2.490

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.